NanoView Biosciences: Jan Lötvall, Mark Plavsic

NanoView Biosciences, a developer of liquid biopsy technologies, has appointed Jan Lötvall and Mark Plavsic to the company's scientific advisory board. Lötvall is a professor at the University of Gothenburg in Sweden. He directs a research lab studying extracellular vesicles and is a medical specialist in both clinical allergy and clinical pharmacology, with experience in translational studies of inflammation and cancer. Lötvall is the founding editor and current editor-in-chief of the Journal of Extracellular Vesicles and has previously served as chief scientist at Codiak BioSciences.

Plavsic is the chief technical officer (CTO) at Fate Therapeutics. He has also previously served as CTO at Lysogene, head of product safety and global manufacturing process improvement in Sanofi Genzyme's Technical Operations unit, and head of gene therapy development in the same company's Technology Development unit.